Neurocrine Biosciences, Inc. (0K6R.L)
USD 98.2
(-7.23%)
USD 98.2
(-7.23%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 3.25 Billion USD | 37.27% |
| 2022 | 2.36 Billion USD | 14.29% |
| 2021 | 2.07 Billion USD | 19.47% |
| 2020 | 1.73 Billion USD | 32.83% |
| 2019 | 1.3 Billion USD | 31.5% |
| 2018 | 993.15 Million USD | 21.47% |
| 2017 | 817.59 Million USD | 123.94% |
| 2016 | 365.08 Million USD | -23.1% |
| 2015 | 474.78 Million USD | 95.36% |
| 2014 | 243.03 Million USD | 57.12% |
| 2013 | 154.67 Million USD | -21.08% |
| 2012 | 195.97 Million USD | 41.64% |
| 2011 | 138.36 Million USD | -4.19% |
| 2010 | 144.42 Million USD | 103.94% |
| 2009 | 70.81 Million USD | -40.08% |
| 2008 | 118.18 Million USD | -57.28% |
| 2007 | 276.65 Million USD | -29.0% |
| 2006 | 389.67 Million USD | -19.34% |
| 2005 | 483.12 Million USD | -6.95% |
| 2004 | 519.21 Million USD | -6.44% |
| 2003 | 554.95 Million USD | 108.21% |
| 2002 | 266.53 Million USD | -23.04% |
| 2001 | 346.35 Million USD | 86.25% |
| 2000 | 185.96 Million USD | 70.29% |
| 1999 | 109.2 Million USD | 35.65% |
| 1998 | 80.5 Million USD | -12.4% |
| 1997 | 91.9 Million USD | 17.82% |
| 1996 | 78 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 3.47 Billion USD | 6.8% |
| 2024 Q2 | 3.3 Billion USD | -4.82% |
| 2024 Q3 | 3.53 Billion USD | 6.96% |
| 2023 Q3 | 2.84 Billion USD | 9.0% |
| 2023 Q1 | 2.35 Billion USD | -0.38% |
| 2023 Q4 | 3.25 Billion USD | 14.16% |
| 2023 Q2 | 2.61 Billion USD | 10.73% |
| 2023 FY | 3.25 Billion USD | 37.27% |
| 2022 Q2 | 2 Billion USD | -6.47% |
| 2022 Q4 | 2.36 Billion USD | 10.51% |
| 2022 Q1 | 2.14 Billion USD | 3.47% |
| 2022 FY | 2.36 Billion USD | 14.29% |
| 2022 Q3 | 2.14 Billion USD | 6.87% |
| 2021 FY | 2.07 Billion USD | 19.47% |
| 2021 Q1 | 1.84 Billion USD | 6.44% |
| 2021 Q2 | 1.95 Billion USD | 5.96% |
| 2021 Q3 | 2.01 Billion USD | 3.11% |
| 2021 Q4 | 2.07 Billion USD | 2.74% |
| 2020 Q4 | 1.73 Billion USD | 15.45% |
| 2020 FY | 1.73 Billion USD | 32.83% |
| 2020 Q3 | 1.5 Billion USD | -0.86% |
| 2020 Q2 | 1.51 Billion USD | 11.29% |
| 2020 Q1 | 1.36 Billion USD | 4.28% |
| 2019 Q1 | 957.72 Million USD | -3.57% |
| 2019 Q2 | 1.06 Billion USD | 11.4% |
| 2019 Q3 | 1.17 Billion USD | 10.6% |
| 2019 Q4 | 1.3 Billion USD | 10.68% |
| 2019 FY | 1.3 Billion USD | 31.5% |
| 2018 Q4 | 993.15 Million USD | 6.36% |
| 2018 Q1 | 806.36 Million USD | -1.37% |
| 2018 Q2 | 841.31 Million USD | 4.34% |
| 2018 Q3 | 933.74 Million USD | 10.99% |
| 2018 FY | 993.15 Million USD | 21.47% |
| 2017 Q1 | 289.36 Million USD | -20.74% |
| 2017 Q4 | 817.59 Million USD | 5.84% |
| 2017 Q3 | 772.49 Million USD | 2.44% |
| 2017 Q2 | 754.08 Million USD | 160.6% |
| 2017 FY | 817.59 Million USD | 123.94% |
| 2016 Q3 | 399.16 Million USD | -7.14% |
| 2016 Q4 | 365.08 Million USD | -8.54% |
| 2016 Q1 | 459.33 Million USD | -3.25% |
| 2016 FY | 365.08 Million USD | -23.1% |
| 2016 Q2 | 429.83 Million USD | -6.42% |
| 2015 Q2 | 511.2 Million USD | -3.14% |
| 2015 FY | 474.78 Million USD | 95.36% |
| 2015 Q3 | 492.43 Million USD | -3.67% |
| 2015 Q4 | 474.78 Million USD | -3.58% |
| 2015 Q1 | 527.77 Million USD | 117.16% |
| 2014 Q3 | 257.75 Million USD | -4.37% |
| 2014 Q2 | 269.53 Million USD | -3.49% |
| 2014 FY | 243.03 Million USD | 57.12% |
| 2014 Q1 | 279.29 Million USD | 80.57% |
| 2014 Q4 | 243.03 Million USD | -5.71% |
| 2013 Q4 | 154.67 Million USD | -6.8% |
| 2013 FY | 154.67 Million USD | -21.08% |
| 2013 Q3 | 165.96 Million USD | -5.06% |
| 2013 Q1 | 183.92 Million USD | -6.15% |
| 2013 Q2 | 174.81 Million USD | -4.95% |
| 2012 Q1 | 210.14 Million USD | 51.87% |
| 2012 Q2 | 202.08 Million USD | -3.83% |
| 2012 Q3 | 193.25 Million USD | -4.37% |
| 2012 Q4 | 195.97 Million USD | 1.41% |
| 2012 FY | 195.97 Million USD | 41.64% |
| 2011 FY | 138.36 Million USD | -4.19% |
| 2011 Q4 | 138.36 Million USD | -7.15% |
| 2011 Q3 | 149.02 Million USD | 16.97% |
| 2011 Q2 | 127.4 Million USD | -4.92% |
| 2011 Q1 | 133.99 Million USD | -7.22% |
| 2010 Q1 | 79.88 Million USD | 12.8% |
| 2010 FY | 144.42 Million USD | 103.94% |
| 2010 Q4 | 144.42 Million USD | -3.67% |
| 2010 Q3 | 149.93 Million USD | -3.3% |
| 2010 Q2 | 155.04 Million USD | 94.09% |
| 2009 Q4 | 70.81 Million USD | -6.71% |
| 2009 Q2 | 86.86 Million USD | -14.01% |
| 2009 FY | 70.81 Million USD | -40.08% |
| 2009 Q1 | 101.02 Million USD | -14.51% |
| 2009 Q3 | 75.9 Million USD | -12.62% |
| 2008 Q3 | 207.73 Million USD | -7.95% |
| 2008 FY | 118.18 Million USD | -57.28% |
| 2008 Q1 | 243.88 Million USD | -11.85% |
| 2008 Q2 | 225.67 Million USD | -7.47% |
| 2008 Q4 | 118.18 Million USD | -43.11% |
| 2007 Q4 | 276.65 Million USD | -12.86% |
| 2007 FY | 276.65 Million USD | -29.0% |
| 2007 Q3 | 317.49 Million USD | -7.13% |
| 2007 Q2 | 341.86 Million USD | -6.01% |
| 2007 Q1 | 363.71 Million USD | -6.66% |
| 2006 Q2 | 442.54 Million USD | -7.3% |
| 2006 FY | 389.67 Million USD | -19.34% |
| 2006 Q4 | 389.67 Million USD | -3.58% |
| 2006 Q1 | 477.4 Million USD | -1.18% |
| 2006 Q3 | 404.13 Million USD | -8.68% |
| 2005 Q3 | 500.96 Million USD | 5.35% |
| 2005 FY | 483.12 Million USD | -6.95% |
| 2005 Q1 | 486.36 Million USD | -6.33% |
| 2005 Q2 | 475.51 Million USD | -2.23% |
| 2005 Q4 | 483.12 Million USD | -3.56% |
| 2004 Q1 | 577.26 Million USD | 4.02% |
| 2004 Q3 | 552.61 Million USD | 1.12% |
| 2004 Q2 | 546.47 Million USD | -5.33% |
| 2004 Q4 | 519.21 Million USD | -6.04% |
| 2004 FY | 519.21 Million USD | -6.44% |
| 2003 FY | 554.95 Million USD | 108.21% |
| 2003 Q3 | 552.4 Million USD | 48.19% |
| 2003 Q2 | 372.76 Million USD | 2.68% |
| 2003 Q1 | 363.04 Million USD | 36.21% |
| 2003 Q4 | 554.95 Million USD | 0.46% |
| 2002 FY | 266.53 Million USD | -23.04% |
| 2002 Q3 | 298.64 Million USD | -4.09% |
| 2002 Q4 | 266.53 Million USD | -10.75% |
| 2002 Q2 | 311.36 Million USD | -5.15% |
| 2002 Q1 | 328.28 Million USD | -5.22% |
| 2001 Q4 | 346.35 Million USD | 94.63% |
| 2001 FY | 346.35 Million USD | 86.25% |
| 2001 Q1 | 172.83 Million USD | -7.06% |
| 2001 Q2 | 163.62 Million USD | -5.33% |
| 2001 Q3 | 177.95 Million USD | 8.76% |
| 2000 FY | 185.96 Million USD | 70.29% |
| 2000 Q1 | 106.39 Million USD | -2.57% |
| 2000 Q2 | 97.9 Million USD | -7.98% |
| 2000 Q3 | 96.26 Million USD | -1.68% |
| 2000 Q4 | 185.96 Million USD | 93.19% |
| 1999 Q1 | 74.6 Million USD | -7.33% |
| 1999 Q2 | 70.6 Million USD | -5.36% |
| 1999 Q3 | 68.3 Million USD | -3.26% |
| 1999 Q4 | 109.2 Million USD | 59.88% |
| 1999 FY | 109.2 Million USD | 35.65% |
| 1998 Q2 | 83.5 Million USD | -5.44% |
| 1998 Q4 | 80.5 Million USD | -7.36% |
| 1998 Q1 | 88.3 Million USD | -3.92% |
| 1998 FY | 80.5 Million USD | -12.4% |
| 1998 Q3 | 86.9 Million USD | 4.07% |
| 1997 Q2 | 84 Million USD | 1.33% |
| 1997 Q4 | 91.9 Million USD | 8.24% |
| 1997 Q1 | 82.9 Million USD | 6.28% |
| 1997 FY | 91.9 Million USD | 17.82% |
| 1997 Q3 | 84.9 Million USD | 1.07% |
| 1996 Q4 | 78 Million USD | 8.03% |
| 1996 Q2 | 73.4 Million USD | 161.21% |
| 1996 Q1 | 28.1 Million USD | 0.0% |
| 1996 FY | 78 Million USD | 0.0% |
| 1996 Q3 | 72.2 Million USD | -1.63% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| uniQure N.V. | 831.68 Million USD | -290.939% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | -246.957% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | -317.982% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -1864.545% |
| bluebird bio, Inc. | 619.16 Million USD | -425.13% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -2483.675% |
| Imunon, Inc. | 21.91 Million USD | -14734.336% |
| Editas Medicine, Inc. | 499.15 Million USD | -551.383% |
| IQVIA Holdings Inc. | 26.68 Billion USD | 87.814% |
| Mettler-Toledo International Inc. | 3.35 Billion USD | 3.104% |
| Myriad Genetics, Inc. | 1.19 Billion USD | -171.244% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | -130.763% |
| Verastem, Inc. | 149.71 Million USD | -2071.683% |
| Walgreens Boots Alliance, Inc. | 81.03 Billion USD | 95.988% |
| Waters Corporation | 4.62 Billion USD | 29.728% |
| Thermo Fisher Scientific Inc. | 98.72 Billion USD | 96.707% |
| Biogen Inc. | 26.84 Billion USD | 87.888% |
| Nektar Therapeutics | 398.03 Million USD | -716.867% |
| Perrigo Company plc | 10.8 Billion USD | 69.92% |
| Dynavax Technologies Corporation | 997.09 Million USD | -226.087% |
| Illumina, Inc. | 10.11 Billion USD | 67.843% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -11400.265% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | -316.659% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -1361.264% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -4849.612% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 52.476% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -1866.731% |
| Evolus, Inc. | 188.99 Million USD | -1620.336% |
| Adicet Bio, Inc. | 207.29 Million USD | -1468.489% |
| Aclaris Therapeutics, Inc. | 197.4 Million USD | -1547.071% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 90.171% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | -1479.914% |
| FibroGen, Inc. | 423.52 Million USD | -667.692% |
| Agilent Technologies, Inc. | 10.76 Billion USD | 69.791% |
| OPKO Health, Inc. | 2.01 Billion USD | -61.625% |
| Homology Medicines, Inc. | 47.05 Million USD | -6809.493% |
| Geron Corporation | 394.07 Million USD | -725.069% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 15.104% |
| Exelixis, Inc. | 2.94 Billion USD | -10.503% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -782.358% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -2006.02% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | -149.92% |
| Zoetis Inc. | 14.28 Billion USD | 77.241% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | -452.737% |
| Abeona Therapeutics Inc. | 64 Million USD | -4980.154% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 85.696% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -5711.364% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | -8.74% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 0.404% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | -423.139% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | -87.588% |
| Blueprint Medicines Corporation | 1.04 Billion USD | -209.878% |
| Insmed Incorporated | 1.32 Billion USD | -144.496% |
| TG Therapeutics, Inc. | 329.58 Million USD | -886.507% |
| Incyte Corporation | 6.78 Billion USD | 52.059% |
| Emergent BioSolutions Inc. | 1.83 Billion USD | -77.198% |